Related Experiment Videos
OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell
S J Pirruccello1, J D Jackson, M S Lang
1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198.
Abstract:
OMA-AML-1 was established from a patient with acute myelomonocytic (M4) leukemia at fifth relapse when blasts were greater than 85% CD34+, CD15-. Leukemic cells were established in suspension culture and independently grown as subcutaneous tumors in SCID mice. Cells growing in suspension culture underwent differentiation by phenotypic and morphologic criteria. In contrast, cells grown as subcutaneous solid tumors in SCID mice maintained progenitor cell characteristics with high-density CD34 expression and lack of morphologic differentiation. A tendency toward differentiation to CD15+, CD34- cells in vitro and self-renewal of CD34+, CD15- cells in vivo was consistently demonstrated regardless of whether cells were initially grown in vitro or in vivo. The cell line maintains both a CD34+, CD15- progentitor cell pool and a non-overlapping, CD15+, CD34- differentiating cell compartment after more than 1 year in continuous culture. Cell cycle analysis and cloning experiments were consistent with terminal differentiation occurring in the CD15+, CD34- population. The cell line shows concentration-dependent proliferative responses to interleukin (IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-6, but not to granulocyte CSF (G-CSF). OMA-AML-1 appears to mimic several features of normal myeloid hematopoiesis and should prove useful for the study of normal and malignant myeloid differentiation.
Insights
A novel acute myelomonocytic leukemia (M4) cell line, OMA-AML-1, was developed. This cell line maintains both progenitor and differentiating cell populations, useful for studying myeloid differentiation.
Area of Science:
- Hematology
- Cell Biology
- Cancer Research
Background:
- Acute myelomonocytic leukemia (M4) is a challenging subtype of acute myeloid leukemia.
- Establishing reliable cell lines that mimic primary leukemia is crucial for research.
Purpose of the Study:
- To establish and characterize a new cell line, OMA-AML-1, from a relapsed M4 leukemia patient.
- To investigate the maintenance of progenitor and differentiating cell populations within the cell line.
Main Methods:
- Cell line establishment from patient sample and xenograft models.
- Flow cytometry (CD34, CD15 expression) and morphologic analysis.
- In vitro and in vivo culture conditions, cell cycle analysis, and cytokine response assays.
Main Results:
- OMA-AML-1 cells exhibited distinct phenotypes in vitro (differentiation) and in vivo (progenitor maintenance).
- The cell line consistently maintained both CD34+, CD15- progenitor and CD15+, CD34- differentiating compartments.
- Proliferative responses to IL-3, GM-CSF, and IL-6 were observed, but not G-CSF.
Conclusions:
- OMA-AML-1 is a valuable new cell line that recapitulates key features of normal myeloid hematopoiesis.
- This cell line provides a model for studying normal and malignant myeloid differentiation and leukemia biology.